

SUPPLEMENTARY DATA

Annotation of statistical models analyzed in this study

For the weight loss outcomes (6-month and 2-year), the following linear model is fitted to the pooled sample if no significant interactions between SNP and treatment groups.

$$WL_i = \beta_0 + \beta_{W0}W0_i + \beta_S S_i + \beta_{LS} LS_i + \beta_{ME} ME_i + \beta_A A_i + \beta_M M_i + \beta_{AA} AA_i + \beta_H H_i + \beta_{AP} AP_i + \beta_{AI} AI_i + \varepsilon_i$$

WL_i : the weight loss outcome for the i th subject

β_0 : Intercept

$W0_i$: Weight at baseline for subject i

S_i : Number of effective alleles (0,1,2) of the SNP under test in subject i

LS_i, ME_i : Indicators for subject i belonging to the Lifestyle and Metformin groups respectively

A_i : Subject i 's age at baseline

M_i : Indicator for subject i being a man

AA_i, H_i, AP_i, AI_i : Indicators for subject i being an African American, Hispanic, Asian or Pacific Islander, American Indian, respectively

$\beta_{W0}, \beta_S, \beta_{LS}, \beta_{ME}, \beta_A, \beta_M, \beta_{AA}, \beta_H, \beta_{AP}, \beta_{AI}$: Regression coefficients for the corresponding covariate

ε_i : Independent random errors following a mean-zero normal distribution with constant variance.

In the presence of significant interactions between SNP and treatment groups, the following linear regression model is fitted within each treatment group

$$WL_i = \beta_0 + \beta_{W0}W0_i + \beta_S S_i + \beta_A A_i + \beta_M M_i + \beta_{AA} AA_i + \beta_H H_i + \beta_{AP} AP_i + \beta_{AI} AI_i + \varepsilon_i$$

In this case, three sets of treatment-specific coefficient estimates will be output.

For the weight regain outcome, subjects could have more than one regain rate measure at different time points during the followup after 6 month. The following two linear mixed models are fitted for each of the 16 SNPs in either the pooled sample or the treatment-specific samples.

$$WL_{ij} = \beta_0 + \beta_{W0}W0_i + \beta_S S_i + \beta_{LS} LS_i + \beta_{ME} ME_i + \beta_A A_i + \beta_M M_i + \beta_{AA} AA_i + \beta_H H_i + \beta_{AP} AP_i + \beta_{AI} AI_i + \varepsilon_{ij}$$

$$WL_{ij} = \beta_0 + \beta_{W0}W0_i + \beta_S S_i + \beta_A A_i + \beta_M M_i + \beta_{AA} AA_i + \beta_H H_i + \beta_{AP} AP_i + \beta_{AI} AI_i + \varepsilon_{ij}$$

for the j th weight regain measure in subject i . Notice the error terms within the same subject ε_{ij} are no longer independent, instead an auto-regressive covariance structure is assumed where the correlation coefficient between ε_{ij} decreases exponentially. That is, if the correlation coefficient between ε_{i1} and ε_{i2} is ρ , the correlation coefficient between ε_{i1} and ε_{i3} would be ρ^2 .

Genetic risk scores (GRS) and weight-regain from 6 months through study end

We constructed three GRS comprising: i) all measured SNPs coded with the effect alleles as those associated with baseline BMI in the DPP; ii) SNPs associated with weight-regain in the overall DPP cohort (as described above); iii) all SNPs showing statistically significant gene x lifestyle interactions, where the SNP effect estimate on weight-regain differed in magnitude between the lifestyle and placebo arms of the trial. As Supplemental Figure 1 illustrates, weight regain rates were comparable between the lifestyle and placebo arms for participants with a low GRS (Supplemental Figures 1A-C), but differed substantially in those with a high GRS, indicating that persons with a heavy genetic burden struggle to maintain reduced weight when engaging in programs of intensive lifestyle modification.

The first GRS model showed no overall association with rate of weight-regain ($P=0.13$). The second GRS yielded similar effects across three arms ($P_{interaction}=0.70$), with one unit (allele) increase conveying 0.22, 0.37 and 0.31 kg/yr/allele faster weight-regain rates in the lifestyle ($P=0.04$), metformin ($P=0.01$) and placebo ($P=0.11$) groups respectively (panel B). On average, the second GRS was associated with 0.28kg/yr/allele faster ($P=0.0006$) rate of weight-regain. The third GRS effects (panel C) differed by treatment ($P_{interaction}=0.005$), with -0.35, -0.08, and 0.40 kg/yr/allele weight-regain rates in the lifestyle ($P=0.01$), metformin ($P=0.64$), and placebo ($P=0.09$) groups, respectively.

Mediation analyses

Secondary analyses were performed to determine whether changes in selected behaviors mediated associations between genotypes and obesity traits. SNPs significantly affecting each of these three traits were selected. Each SNP-outcome combination was tested for potential mediators. Candidate mediators were diet adherence, leisure time physical activity (LTPA), percent calories from protein, snack frequency, sweet and dessert frequency, fruit frequency and vegetable frequency. While testing each candidate mediator, two models were fit separately with the only difference being whether or not the candidate mediator was included as a covariate in the model. The same linear or mixed model (depending on outcome) was employed. From each pair of models, the difference in the two SNP regression coefficients and the standard errors of these differences were calculated. In these analyses, a statistically significant non-zero difference represents a discrepancy between the marginal SNP effect estimate and the SNP effect estimate that is conditional on the putative mediator, thus validating the intermediate function of the mediator from genotype to the outcome.

Although a number of nominally statistically significant associations were observed between SNPs and candidate energy balance behaviors (data not shown), there was no reliable evidence that any of these factors mediated the SNP effects on weight variables after correcting for multiple statistical comparisons (data not shown).

SUPPLEMENTARY DATA

**Pennington Biomedical Research Center
(Baton Rouge, LA)**

George A. Bray, MD*
Iris W. Culbert, BSN, RN, CCRC**
Catherine M. Champagne, PhD, RD
Barbara Eberhardt, RD, LDN
Frank Greenway, MD
Fonda G. Guillory, LPN
April A. Herbert, RD
Michael L. Jeffirs, LPN
Betty M. Kennedy, MPA
Jennifer C. Lovejoy, PhD
Laura H. Morris, BS
Lee E. Melancon, BA, BS
Donna Ryan, MD
Deborah A. Sanford, LPN
Kenneth G. Smith, BS, MT
Lisa L. Smith, BS
Julia A. St.Amant, RTR
Richard T. Tulley, PhD
Paula C. Vicknair, MS, RD
Donald Williamson, PhD
Jeffery J. Zachwieja, PhD

University of Chicago (Chicago, IL)

Kenneth S. Polonsky, MD*
Janet Tobian, MD, PhD*
David Ehrmann, MD*
Margaret J. Matulik, RN, BSN**
Bart Clark, MD
Kirsten Czech, MS
Catherine DeSandre, BA
Ruthanne Hilbrich, RD
Wylie McNabb, EdD
Ann R. Semenske, MS, RD

Jefferson Medical College (Philadelphia, PA)

Jose F. Caro, MD*
Pamela G. Watson, RN, ScD*
Barry J. Goldstein, MD, PhD*
Kellie A. Smith, RN, MSN**
Jewel Mendoza, RN, BSN**
Renee Liberoni, MPH
Constance Pepe, MS, RD
John Spandorfer, MD

University of Miami (Miami, FL)

Richard P. Donahue, PhD*
Ronald B. Goldberg, MD*
Ronald Prineas, MD, PhD*
Patricia Rowe, MPA**
Jeanette Calles, MSED
Paul Cassanova-Romero, MD
Hermes J. Florez, MD
Anna Giannella, RD, MS
Lascalles Kirby, MS

Carmen Larreal
Valerie McLymont, RN
Jadell Mendez
Juliet Ojito, RN
Arlette Perry, PhD
Patrice Saab, PhD

**The University of Texas Health Science
Center (San Antonio, TX)**

Steven M. Haffner, MD, MPH*
Maria G. Montez, RN, MSHP, CDE**
Carlos Lorenzo, MD, PhD
Arlene Martinez, RN, BSN, CDE

University of Colorado (Denver, CO)

Richard F. Hamman, MD, DrPH*
Patricia V. Nash, MS**
Lisa Testaverde, MS**
Denise R. Anderson, RN, BSN
Larry B. Ballonoff, MD
Alexis Bouffard, MA,
B. Ned Calonge, MD, MPH
Lynne Delve

Martha Farago, RN
James O. Hill, PhD
Shelley R. Hoyer, BS
Bonnie T. Jortberg, MS, RD, CDE
Dione Lenz, RN, BSN
Marsha Miller, MS, RD
David W. Price, MD
Judith G. Regensteiner, PhD
Helen Seagle, MS, RD
Carissa M. Smith, BS
Sheila C. Steinke, MS
Brent VanDorsten, PhD

Joslin Diabetes Center (Boston, MA)

Edward S. Horton, MD*
Kathleen E. Lawton, RN**
Ronald A. Arky, MD
Marybeth Bryant
Jacqueline P. Burke, BSN
Enrique Caballero, MD
Karen M. Callaphan, BA
Om P. Ganda, MD
Therese Franklin
Sharon D. Jackson, MS, RD, CDE
Alan M. Jacobsen, MD
Lyn M. Kula, RD
Margaret Kocal, RN, CDE
Maureen A. Malloy, BS
Maryanne Nicosia, MS, RD
Cathryn F. Oldmixon, RN
Jocelyn Pan, BS, MPH
Marizel Quitingon
Stacy Rubtchinsky, BS

SUPPLEMENTARY DATA

Ellen W. Seely, MD
Dana Schweizer, BSN
Donald Simonson, MD
Fannie Smith, MD
Caren G. Solomon, MD, MPH
James Warram, MD
**VA Puget Sound Health Care System and
University of Washington (Seattle, WA)**

Steven E. Kahn, MB, ChB*
Brenda K. Montgomery, RN, BSN, CDE**
Wilfred Fujimoto, MD
Robert H. Knopp, MD
Edward W. Lipkin, MD
Michelle Marr, BA
Dace Trence, MD

University of Tennessee (Memphis, TN)

Abbas E. Kitabchi, PhD, MD, FACP*
Mary E. Murphy, RN, MS, CDE, MBA**
William B. Applegate, MD, MPH
Michael Bryer-Ash, MD
Sandra L. Frieson, RN

Raed Imseis, MD
Helen Lambeth, RN, BSN
Lynne C. Lichtermann, RN, BSN
Hooman Oktaei, MD

Lily M.K. Rutledge, RN, BSN
Amy R. Sherman, RD, LD
Clara M. Smith, RD, MHP, LDN
Judith E. Soberman, MD
Beverly Williams-Cleaves, MD

Northwestern University's Feinberg School of Medicine (Chicago, IL)

Boyd E. Metzger, MD*
Mariana K. Johnson, MS, RN**
Catherine Behrends
Michelle Cook, MS
Marian Fitzgibbon, PhD
Mimi M. Giles, MS, RD
Deloris Heard, MA
Cheryl K.H. Johnson, MS, RN
Diane Larsen, BS
Anne Lowe, BS
Megan Lyman, BS
David McPherson, MD
Mark E. Molitch, MD
Thomas Pitts, MD
Renee Reinhart, RN, MS
Susan Roston, RN, RD
Pamela A. Schinleber, RN, MS

Massachusetts General Hospital (Boston, MA)

David M. Nathan, MD*
Charles McKittrick, BSN**

Heather Turgeon, BSN**
Kathy Abbott
Ellen Anderson, MS, RD
Laurie Bissett, MS, RD
Enrico Cagliero, MD
Jose C. Florez, MD, PhD+
Linda Delahanty, MS, RD
Valerie Goldman, MS, RD
Alexandra Poulos
**University of California-San Diego (San
Diego, CA)**

Jerrold M. Olefsky, MD*
Mary Lou Carrion-Petersen, RN, BSN**
Elizabeth Barrett-Connor, MD
Steven V. Edelman, MD

Robert R. Henry, MD
Javiva Horne, RD
Simona Szerdi Janesch, BA
Diana Leos, RN, BSN
Sundar Mudaliar, MD
William Polonsky, PhD
Jean Smith, RN
Karen Vejvoda, RN, BSN, CDE, CCRC

St. Luke's-Roosevelt Hospital (New York, NY)

F. Xavier Pi-Sunyer, MD*
Jane E. Lee, MS**
David B. Allison, PhD
Nancy J. Aronoff, MS, RD
Jill P. Crandall, MD

Sandra T. Foo, MD
Carmen Pal, MD
Kathy Parkes, RN
Mary Beth Pena, RN
Ellen S. Rooney, BA
Gretchen E.H. Van Wye, MA
Kristine A. Viscovich, ANP

Indiana University (Indianapolis, IN)

David G. Marrero, PhD*
Melvin J. Prince, MD*
Susie M. Kelly, RN, CDE**
Yolanda F. Dotson, BS
Edwin S. Fineberg, MD
John C. Guare, PhD
Angela M. Hadden
James M. Ignaut, MA
Marcia L. Jackson
Marion S. Kirkman, MD
Kieren J. Mather, MD
Beverly D. Porter, MSN
Paris J. Roach, MD
Nancy D. Rowland, BS, MS
Madelyn L. Wheeler, RD

SUPPLEMENTARY DATA

Medstar Research Institute (Washington, DC)

Robert E. Ratner, MD*
Gretchen Youssef, RD, CDE**
Sue Shapiro, RN, BSN, CCRC**
Catherine Bavido-Arrage, MS, RD, LD
Geraldine Boggs, MSN, RN
Marjorie Bronsord, MS, RD, CDE
Ernestine Brown
Wayman W. Cheatham, MD
Susan Cola
Cindy Evans
Peggy Gibbs
Tracy Kellum, MS, RD, CDE
Claresa Levatan, MD
Asha K. Nair, BS
Maureen Passaro, MD
Gabriel Uwaifo, MD

University of Southern California/UCLA Research Center (Alhambra, CA)

Mohammed F. Saad, MD*
Maria Budget**
Sujata Jinagouda, MD**
Khan Akbar, MD
Claudia Conzues
Perpetua Magpuri
Kathy Ngo
Amer Rassam, MD
Debra Waters
Kathy Xapthalamous

Washington University (St. Louis, MO)

Julio V. Santiago, MD* (deceased)
Samuel Dagogo-Jack, MD, MSc, FRCP, FACP*
Neil H. White, MD, CDE*
Samia Das, MS, MBA, RD, LD**
Ana Santiago, RD**
Angela Brown, MD
Edwin Fisher, PhD
Emma Hurt, RN
Tracy Jones, RN
Michelle Kerr, RD
Lucy Ryder, RN
Cormarie Wernimont, MS, RD

Johns Hopkins School of Medicine (Baltimore, MD)

Christopher D. Saudek, MD*
Vanessa Bradley, BA**
Emily Sullivan, MEd, RN**
Tracy Whittington, BS**
Caroline Abbas
Frederick L. Brancati, MD, MHS
Jeanne M. Clark, MD
Jeanne B. Charleston, RN, MSN

Janice Freel
Katherine Horak, RD
Dawn Jiggetts
Deloris Johnson
Hope Joseph
Kimberly Loman
Henry Mosley
Richard R. Rubin, PhD
Alafia Samuels, MD
Kerry J. Stewart, EdD
Paula Williamson

University of New Mexico (Albuquerque, NM)

David S. Schade, MD*
Karwyn S. Adams, RN, MSN**
Carolyn Johannes, RN, CDE**
Leslie F. Adler, PhD
Patrick J. Boyle, MD
Mark R. Burge, MD
Janene L. Canady, RN, CDE
Lisa Chai, RN
Ysela Gonzales, RN, MSN
Doris A. Hernandez-McGinnis
Patricia Katz, LPN
Carolyn King
Amer Rassam, MD
Sofya Rubinchik, MD
Willette Senter, RD
Debra Waters, PhD

Albert Einstein College of Medicine (Bronx, NY)

Harry Shamoan, MD*
Janet O. Brown, RN, MPH, MSN**
Elsie Adorno, BS
Liane Cox, MS, RD
Jill Crandall, MD
Helena Duffy, MS, C-ANP
Samuel Engel, MD
Allison Friedler, BS
Crystal J. Howard-Century, MA
Stacey Kloiber, RN
Nadege Longchamp, LPN
Helen Martinez, RN, MSN, FNP-C
Dorothy Pompei, BA
Jonathan Scheindlin, MD
Elissa Violino, RD, MS
Elizabeth Walker, RN, DNSc, CDE
Judith Wylie-Rosett, EdD, RD
Elise Zimmerman, RD, MS
Joel Zonszein, MD

University of Pittsburgh (Pittsburgh, PA)

Trevor Orchard, MD*
Rena R. Wing, PhD*

SUPPLEMENTARY DATA

Gaye Koenning, MS, RD**
M. Kaye Kramer, BSN, MPH**
Susan Barr, BS
Miriam Boraz
Lisa Clifford, BS
Rebecca Culyba, BS
Marlene Frazier
Ryan Gilligan, BS
Susan Harrier, MLT
Louann Harris, RN
Susan Jeffries, RN, MSN
Andrea Kriska, PhD
Qurashia Manjoo, MD
Monica Mullen, MHP, RD
Alicia Noel, BS
Amy Otto, PhD
Linda Semler, MS, RD
Cheryl F. Smith, PhD
Marie Smith, RN, BSN
Elizabeth Venditti, PhD
Valarie Weinzierl, BS
Katherine V. Williams, MD, MPH
Tara Wilson, BA

University of Hawaii (Honolulu, HI)

Richard F. Arakaki, MD*
Renee W. Latimer, BSN, MPH**
Narleen K. Baker-Ladao, BS
Ralph Beddow, MD
Lorna Dias, AA
Jillian Inouye, RN, PhD
Marjorie K. Mau, MD
Kathy Mikami, BS, RD
Pharis Mohideen, MD
Sharon K. Odom, RD, MPH
Raynette U. Perry, AA

Southwest American Indian Centers (Phoenix, AZ; Shiprock, NM; Zuni, NM)

William C. Knowler, MD, DrPH**
Norman Coeoyate**
Mary A. Hoskin, RD, MS**
Carol A. Percy, RN, MS**
Kelly J. Acton, MD, MPH
Vickie L. Andre, RN, FNP
Rosalyn Barber
Shandiin Begay, MPH
Peter H. Bennett, MB, FRCP
Mary Beth Benson, RN, BSN
Evelyn C. Bird, RD, MPH
Brenda A. Broussard, RD, MPH, MBA, CDE
Marcella Chavez, RN, AS
Tara Dacawyma
Matthew S. Doughty, MD
Roberta Duncan, RD

Cyndy Edgerton, RD
Jacqueline M. Ghahate
Justin Glass, MD
Martia Glass, MD
Dorothy Gohdes, MD
Wendy Grant, MD
Robert L. Hanson, MD, MPH
Ellie Horse
Louise E. Ingraham, MS, RD, LN
Merry Jackson
Priscilla Jay
Roylen S. Kaskalla
David Kessler, MD
Kathleen M. Kobus, RNC-ANP
Jonathan Krakoff, MD
Catherine Manus, LPN
Sara Michaels, MD
Tina Morgan
Yolanda Nashboo (deceased)
Julie A. Nelson, RD
Steven Poirier, MD
Evette Polczynski, MD
Mike Reidy, MD
Jeanine Roumain, MD, MPH
Debra Rowse, MD
Sandra Sangster
Janet Sewenemewa
Darryl Tonemah, PhD
Charlton Wilson, MD
Michelle Yazzie
**George Washington University Biostatistics
Center (DPP Coordinating Center Rockville,
MD)**
Raymond Bain, PhD*
Sarah Fowler, PhD*
Tina Brennehan**
Solome Abebe
Julie Bamdad, MS
Jackie Callaghan
Sharon L. Edelstein, ScM
Yuping Gao
Kristina L. Grimes
Nisha Grover
Lori Haffner, MS
Steve Jones
Tara L. Jones
Richard Katz, MD
John M. Lachin, ScD
Pamela Mucik
Robert Orlosky
James Rochon, PhD
Alla Sapozhnikova
Hanna Sherif, MS

SUPPLEMENTARY DATA

Charlotte Stimpson
Marinella Temprosa, MS
Fredricka Walker-Murray
Central Biochemistry Laboratory (Seattle, WA)

Santica Marcovina, PhD, ScD*
Greg Strylewicz, PhD**
F. Alan Aldrich

Carotid Ultrasound

Dan O'Leary, MD*

CT Scan Reading Center

Elizabeth Stamm, MD*

Epidemiological Cardiology Research Center- Epicare (Winston-Salem, NC)

Pentti Rautaharju, MD, PhD*
Ronald J. Prineas, MD, PhD**

Teresa Alexander
Charles Campbell, MS
Sharon Hall

Yabing Li, MD

Margaret Mills

Nancy Pemberton, MS

Farida Rautaharju, PhD

Zhuming Zhang, MD

Nutrition Coding Center (Columbia, SC)

Elizabeth Mayer-Davis, PhD*

Robert R. Moran, PhD**

Quality of Well-Being Center (La Jolla, CA)

Ted Ganiats, MD*

Kristin David, MHP*

Andrew J. Sarkin, PhD*

NIH/NIDDK (Bethesda, MD)

R. Eastman, MD

Judith Fradkin, MD

Sanford Garfield, PhD

Centers for Disease Control & Prevention

(Atlanta, GA)

Edward Gregg, PhD

Ping Zhang, PhD

University of Michigan (Ann Arbor, MI)

William Herman, MD, MPH

+Genetics Working Group

Jose C. Florez, MD, PhD^{1, 2}

David Altshuler, MD, PhD^{1, 2}

Paul I.W. de Bakker, PhD²

Paul W. Franks, PhD, MPhil, MS^{6, 7}

Robert L. Hanson, MD, MPH³

Kathleen Jablonski, PhD⁵

William C. Knowler, MD, DrPH³

Jarred B. McAteer, AB^{1, 2}

Toni I. Pollin, PhD⁴

Alan R. Shuldiner, MD⁴

1=Massachusetts General Hospital

2=Broad Institute

3=NIDDK

4=University of Maryland

5=Coordinating Center

6=Lund University, Sweden

7=Harvard School of Public Health

*

* denotes Principal Investigator

** denotes Program Coordinator

SUPPLEMENTARY DATA

Supplementary Table 1. Participant characteristics (max N=3,819)

Characteristic	Lifestyle	Metformin	Placebo	Troglitazone	P-value
N	1079	1073	1082	585	
Male	32%	34%	31%	34%	0.404
Baseline age (years)	51 (11)	51 (10)	50 (10)	50 (10)	0.469
Baseline weight (kg)	94 (21)	94 (20)	94 (20)	93 (19)	0.774
Baseline BMI (kg/m ²)	34 (7)	34 (7)	34 (7)	34 (6)	0.311
Baseline waist circumference (cm)	105 (15)	105 (14)	105 (14)	104 (14)	0.605
Baseline SAT L4 (cm ²)	308 (125)	301 (129)	314 (127)		0.449
Baseline SAT L5 (cm ²)	443 (152)	433 (154)	449 (151)		0.408
Baseline VAT L4 (cm ²)	200 (85)	195 (83)	199 (90)		0.701
Baseline VAT L5 (cm ²)	163 (65)	158 (65)	159 (65)		0.500
Baseline LTPA (MET hrs/wk)	16 (22)	16 (26)	17 (29)	15 (16)	0.390
Baseline energy Intake (kJ)	2137 (1071)	2144 (986)	2098 (1052)	2118 (989)	0.739
Short-term weight loss (kg) (0-6 m)	6.7 (5.6)	2.3 (4.0)	0.3 (4.0)		<0.0001
Long-term weight loss (kg) (0-24 m)	5.4 (7.6)	2.1 (5.7)	0.0 (5.5)		<0.0001
Weight regain (kg) (6m to study end)	3.0 (8.2)	2.4 (7.7)	0.8 (7.3)		<0.0001

Data are percentage or Mean (SD), stratified by treatment assignment. P-values from ANOVA F-tests and Chi-Square test of independence. LTPA: leisure-time physical activity. The sample size (N=3,819) is the maximum number used in baseline analyses and includes participants who were subsequently randomized to troglitazone treatment (in which only baseline data is available), in addition to those randomized to lifestyle, metformin, or placebo. Sample sizes for: short-term weight loss (n=3085); long-term weight loss (n=3015); weight regain (n=1411); baseline measures of VAT and SAT (n=869). We include individuals subsequently randomized to troglitazone in the baseline analyses to maximize statistical power. However, these individuals are not included in the prospective analyses as they represent a relatively small subgroup of the DPP population, which is likely underpowered for treatment stratified analyses.

SUPPLEMENTARY DATA

Supplementary Table 2. SNP identities and frequencies

Nearest gene	SNP	Minor(major) allele	Frequency of effect allele	Genotype Frequency		
<i>MC4R</i>	rs17782313	C(T)	n=1646 (23%)	TT (n= 2109, 60%)	CT (n= 1224, 35%)	CC (n= 211, 6%)
<i>FTO</i>	rs9939609	A(T)	n= 2809 (41%)	TT (n= 1235, 36%)	AT (n= 1623, 47%)	AA (n= 593, 17%)
<i>MTCH2</i>	rs10838738	G(A)	n= 2088 (31%)	AA (n= 1679, 49%)	GA (n= 1372, 40%)	GG (n= 358, 11%)
<i>NEGR1</i>	rs2815752	G(A)	n= 2437 (36%)	AA (n= 1440, 42%)	GA (n= 1529, 45%)	GG (n= 454, 13%)
<i>TMEM18</i>	rs6548238	T(C)	n= 1024 (15%)	CC (n= 2484, 72%)	TC (n= 866, 25%)	TT (n= 79, 2%)
<i>SH2B1</i>	rs7498665	C(T)	n= 2524 (37%)	TT(n= 1371, 40%)	CT (n= 1554, 46%)	CC (n= 485, 14%)
<i>SEC16B</i>	rs10913469	C(T)	n= 1395 (21%)	TT(n= 2058, 63%)	CT (n= 1041, 32%)	CC (n= 177, 5%)
<i>BDNF</i>	rs6265	T(C)	n= 1090 (16%)	CC (n= 2442, 71%)	TC (n= 890, 26%)	TT (n= 100, 3%)
<i>FAIM2</i>	rs7138803	A(G)	n= 2144 (32%)	GG (n= 1634, 48%)	AG (n= 1384, 41%)	AA (n= 380, 11%)
<i>KTCD15</i>	rs29941	A(G)	n= 2135 (31%)	GG (n= 1653, 48%)	AG (n= 1401, 41%)	AA (n= 367, 11%)
<i>PPARG</i>	rs1801282	Ala(Pro)	n= 585 (9%)	PP (n= 2787, 83%)	PA (n= 553, 16%)	AA (n= 16, 0%)
<i>LYPLAL1</i>	rs2605100	A(G)	n= 1709 (24%)	GG (n= 2016, 58%)	AG (n= 1267, 36%)	AA (n= 221, 6%)
<i>ETV5</i>	rs7647305	T(C)	n= 1573 (23%)	CC (n= 2091, 61%)	TC (n= 1133, 33%)	TT (n= 220, 6%)
<i>GNPDA2</i>	rs10938397	G(A)	n= 2614 (38%)	AA (n= 1360, 40%)	GA (n= 1546, 45%)	GG (n= 534, 16%)
<i>TFAP2B</i>	rs987237	G(A)	n= 1460 (21%)	AA (n= 2206, 63%)	GA(n= 1084, 31%)	GG (n= 188, 5%)
<i>MSRA</i>	rs7826222	G(C)	n= 1209 (17%)	CC (n= 2423, 69%)	GC (n= 953, 27%)	GG(n= 128, 4%)

SUPPLEMENTARY DATA

Supplementary Table 3. Comparison of risk increasing alleles in the published literature and the DPP for selected SNPs

Nearest gene	SNP	Published studies X-sectional BMI effect allele (other)	Diabetes Prevention Program												
			Baseline BMI	Weight loss at 6m				Weight loss at 24 m				Weight regain			
			All	All	L	M	P	All	L	M	P	All	L	M	P
<i>MC4R</i> ¹	rs17782313	C(T)	T	C	-	-	-	T				T	-	-	-
<i>FTO</i> ¹	rs9939609	A(T)	A	T	-	-	-	-	A	T	T	A	-	-	-
<i>MTCH2</i> ¹	rs10838738	G(A)	A	-	A	A	G	G	-	-	-	A	-	-	-
<i>NEGR1</i> ¹	rs2815752	A(G)	A	G	-	-	-	-	G	G	A	G	-	-	-
<i>TMEM18</i> ¹	rs6548238	C(T)	C	C	-	-	-	C	-	-	-	-	C	C	T
<i>SH2B1</i> ¹	rs7498665	T(C)	T	T	-	-	-	C	-	-	-	T	-	-	-
<i>SEC16B</i> ¹	rs10913469	C(T)	C	C	-	-	-	C	-	-	-	C	-	-	-
<i>BDNF</i> ¹	rs6265	C(T)	T	T	-	-	-	C	-	-	-	C	-	-	-
<i>FAIM2</i> ¹	rs7138803	A(G)	A	A	-	-	-	G	-	-	-	A	-	-	-
<i>KTCD15</i> ¹	rs29941	G(A)	G	A	-	-	-	A	-	-	-	-	G	A	A
<i>PPARG</i> ²	rs1801282	Ala(Pro)	Ala	Pro	-	-	-	Pro	-	-	-	Pro	-	-	-
<i>LYPLAL1</i> ³	rs2605100	G(A)	G	-	G	G	A	G	-	-	-	A	-	-	-
<i>ETV5</i> ¹	rs7647305	C(T)	C	C	-	-	-	T	-	-	-	C	-	-	-
<i>GNPDA2</i> ¹	rs10938397	G(A)	A	-	G	G	G	G	-	-	-	G	-	-	-
<i>TFAP2B</i> ³	rs987237	G(A)	G	A	-	-	-	G	-	-	-	G	-	-	-
<i>MSRA</i> ³	rs7826222	G(C)	G	C	-	-	-	C	-	-	-	C	-	-	-

Effect alleles are from: ¹ Speliotes E.K., *et al.*, Nat Genet. 42(11):937-48. 2010; ² Tönjes A., *et al.* Diabetes Care, 29(11):2489-97. 2006; ³ Lindgren C.M., *et al.*, PLoS Genet. 5(6):e1000508. 2009. Black boxes indicate results that did not reach a nominal level of statistical significance (P<0.05) in the DPP, whereas white boxes are those that did.

*BMI0-baseline BMI; 6m WL- 6 month weight loss; 2y WL – 2 years weight loss; WR – weight regain.

SUPPLEMENTARY DATA

Supplementary Table 4. Summary of association data for each of 16 known obesity loci with baseline weight (kg) and BMI (kg/m²) (N=3,819)

Nearest gene	SNP	Effect(other allele)	Weight (kg/allele)		BMI (kg/m ² /allele)		Height (m/allele)	
			Coefficient(SE)	P-value	Coefficient(SE)	P-value	Coefficient(SE)	P-value
<i>MC4R</i>	rs17782313	C(T)	-0.63(0.52)	0.230	-0.14(0.18)	0.413	-0.30(0.18)	0.099
<i>FTO</i>	rs9939609	A(T)	0.91(0.46)	0.048	0.40(0.15)	0.011	-0.14(0.16)	0.389
<i>MTCH2</i>	rs10838738	G(A)	-0.32(0.50)	0.521	-0.23(0.17)	0.174	0.20(0.17)	0.245
<i>NEGR1</i>	rs2815752	A(G)	-0.35(0.47)	0.462	0.04(0.16)	0.794	-0.37(0.16)	0.025
<i>TMEM18</i>	rs6548238	C(T)	0.60(0.63)	0.339	0.12(0.21)	0.560	0.32(0.22)	0.145
<i>SH2B1</i>	rs7498665	T(C)	-0.04(0.47)	0.931	0.00(0.16)	0.996	-0.09(0.16)	0.586
<i>SEC16B</i>	rs10913469	C(T)	0.57(0.56)	0.303	0.26(0.19)	0.163	-0.09(0.19)	0.635
<i>BDNF</i>	rs6265	C(T)	-1.41(0.62)	0.024	-0.39(0.21)	0.064	-0.27(0.22)	0.214
<i>FAIM2</i>	rs7138803	A(G)	0.51(0.49)	0.299	0.28(0.16)	0.089	-0.24(0.17)	0.160
<i>KTCD15</i>	rs29941	G(A)	0.52(0.49)	0.291	0.27(0.17)	0.109	-0.21(0.17)	0.226
<i>PPARG</i>	rs1801282	Ala(Pro)	-1.82(0.84)	0.030	-0.50(0.28)	0.078	-0.43(0.29)	0.135
<i>LYPLAL1</i>	rs2605100	G(A)	-0.02(0.53)	0.970	0.01(0.18)	0.960	-0.02(0.18)	0.906
<i>ETV5</i>	rs7647305	C(T)	0.79(0.53)	0.136	0.28(0.18)	0.118	-0.01(0.18)	0.949
<i>GNPDA2</i>	rs10938397	G(A)	-1.60(0.46)	0.001	-0.47(0.15)	0.002	-0.20(0.16)	0.207
<i>TFAP2B</i>	rs987237	G(A)	0.16(0.55)	0.772	0.11(0.19)	0.567	-0.23(0.19)	0.244
<i>MSRA</i>	rs7826222	G(C)	-0.02(0.60)	0.971	0.15(0.15)	0.446	-0.41(0.21)	0.049

*Coefficients and P-values correspond to the additive allele effects adjusting for baseline age, sex and ethnicity.

SUPPLEMENTARY DATA

Supplementary Table 5. Summary of association data for each of 16 known obesity loci and rate of weight regain from 6 months through trial end (kg/yr) in non-Hispanic White and by treatment arm

Nearest gene	SNP	Effect(ot her) allele	SN P * TX	TX ADJUSTED coefficient (SE)	P- VAL	LIFESTYLE coefficient (SE)	P- VAL	METFORMIN coefficient (SE)	P- VAL	PLACEBO coefficient (SE)	P- VAL
<i>MC4R</i>	rs17782313	C(T)	N	-0.48 (0.13)	< 0.001	-0.59 (0.18)	< 0.001	-0.15 (0.21)	0.458	-0.68 (0.37)	0.067
<i>FTO</i>	rs9939609	A(T)	Y			0.46 (0.15)	0.002	-0.76 (0.19)	< 0.001	-0.06 (0.30)	0.837
<i>MTCH2</i>	rs10838738	G(A)	Y			-0.32 (0.17)	0.061	-0.04 (0.19)	0.827	0.55 (0.35)	0.114
<i>NEGR1</i>	rs2815752	A(G)	N	-0.38 (0.12)	0.001	-0.29 (0.16)	0.072	-0.50 (0.20)	0.013	-0.36 (0.32)	0.260
<i>TMEM18</i>	rs6548238	C(T)	Y			0.40 (0.21)	0.056	0.54 (0.27)	0.051	-1.13 (0.44)	0.011
<i>SH2B1</i>	rs7498665	T(C)	N	0.17 (0.12)	0.150	0.01 (0.17)	0.937	0.19 (0.19)	0.308	0.59 (0.31)	0.054
<i>SEC16B</i>	rs10913469	C(T)	N	0.08 (0.15)	0.592	0.00 (0.22)	0.987	0.39 (0.23)	0.094	-0.11 (0.43)	0.796
<i>BDNF</i>	rs6265	C(T)	Y			0.21 (0.21)	0.312	0.80 (0.22)	< 0.001	0.88 (0.41)	0.035
<i>FAIM2</i>	rs7138803	A(G)	N	0.13 (0.12)	0.280	0.07 (0.17)	0.688	0.50 (0.20)	0.014	-0.11 (0.32)	0.729
<i>KTCD15</i>	rs29941	G(A)	Y			0.89 (0.17)	< 0.001	-0.56 (0.20)	0.007	-0.71 (0.33)	0.031
<i>PPARG</i>	rs1801282	Ala(Pro)	N	-0.79 (0.18)	< 0.001	-0.91 (0.26)	< 0.001	-0.84 (0.28)	0.003	-0.60 (0.50)	0.234
<i>LYPLAL1</i>	rs2605100	G(A)	N	-0.02 (0.13)	0.845	0.04 (0.18)	0.807	0.06 (0.21)	0.791	-0.43 (0.33)	0.200
<i>ETV5</i>	rs7647305	C(T)	N	-0.13 (0.13)	0.338	-0.50 (0.18)	0.005	0.77 (0.23)	< 0.001	-0.09 (0.37)	0.805
<i>GNPDA2</i>	rs10938397	G(A)	N	0.01 (0.11)	0.899	-0.18 (0.16)	0.258	0.32 (0.19)	0.095	0.10 (0.29)	0.726
<i>TFAP2B</i>	rs987237	G(A)	N	0.19 (0.15)	0.205	0.14 (0.22)	0.528	0.38 (0.22)	0.086	-0.11 (0.35)	0.759
<i>MSRA</i>	rs7826222	G(C)	N	-0.22 (0.16)	0.168	-0.31 (0.22)	0.154	-0.42 (0.25)	0.095	0.47 (0.40)	0.245

SUPPLEMENTARY DATA

Supplementary Figure 1. Mean rate of weight regain from 6 months through 4.5 years (kg/yr) by treatment arm and genetic risk score (GRS) quartiles. Panel A shows a GRS comprised of all 16 SNPs; Panel B shows data for a GRS composed of only those SNPs showing statistically significant main effects for weight regain in the DPP; Panel C shows data for a GRS composed of all SNPs showing statistically significant gene x lifestyle interactions in the DPP.

